Population pharmacokinetics/pharmacodynamics of docetaxel in phase ii studies in patients with cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents, Phytogenic
  • Neoplasms
  • Paclitaxel
  • Taxoids

abstract

  • First-course docetaxel PK is a predictor of first-course hematologic toxicity, but also of fluid retention, which is cumulative in nature. Patients with elevated hepatic enzymes have a 27% reduction in docetaxel CL and are at a higher risk of toxicity. A starting dose of 75 mg/m2 is currently being evaluated in this population. Prospective implementation of large-scale population PK/PD evaluation is feasible in early drug development and this approach generates clinically relevant findings.

publication date

  • January 1998

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 9440742

Additional Document Info

start page

  • 187

end page

  • 96

volume

  • 16

number

  • 1